A research group led by Associate Professor Kota Kodama of the Graduate School of Technology Management, Ritsumeikan University, has been working on the growth of start-up companies from universities and research institutes since 2015, when the average annual sales growth rate of the world's top pharmaceutical companies has increased. It was found that the number of M&As (corporate mergers and acquisitions) has increased significantly.
According to Ritsumeikan University, the research group used a database that records inter-organizational transactions related to pharmaceutical research and development to investigate transactions between companies and research institutes around the world from 2012 to 2021 and identify changes in inter-organizational transaction networks. searched for
As a result, it was suggested that inter-organizational transactions began to disperse from around 2015, and that a new network connecting various groups began to form from 2017.Especially in Europe and the United States, the number of M&As has increased significantly since 2015, suggesting an increase in the number of start-up companies originating from universities and research institutes.In addition, when comparing the average annual sales growth rate of the top 13 companies in terms of global sales before and after 2015, it became clear that there was an increase from 2015.
Although the development of new drugs requires huge investments, the probability of success is low.Efficient research and development is essential to stably bring new drugs to the market, and it is necessary to incorporate knowledge and technology from outside through M&A and joint research.The research group believes that start-ups are helping the pharmaceutical industry achieve innovation in drug discovery and boost sales.
Paper information:[Drug Discovery Today] Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries
